- ►fesemi.org [PDF] MA Khamashta, MJ Cuadrado, F Mujic, NA … - The New England …, 1995 - nejm.highwire.org Vol. 332 No. 15 MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME ... THE
MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME ... M UNTHER A. K HAMASHTA , MD,
M ARIA J OSE C UADRADO , MD, F EDZA ... Cited by 1088 - Related articles - BL Direct - All 12 versions
- ►chestpubs.org J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther, … - Chest, 2008 - chestjournal.chestpubs.org This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is
part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th
Edition). It describes the ... Cited by 903 - Related articles - BL Direct - All 21 versions
JS Levine, D Branch, J Rauch - The New England Journal of Medicine ( …, 2002 - cme.nejm.org From the Department of Medicine, Section of Nephrology, University of Chicago, Chicago (JSL); the
Department of Obstetrics and Gynecol- ogy, University of Utah, Salt Lake City (DWB); and the
Department of Medicine, Division of ... Cited by 828 - Related articles - View as HTML - BL Direct - All 8 versions
LB Goldstein, R Adams, K Becker, CD Furberg, PB … - Circulation, 2001 - Am Heart Assoc As given in Tables 2 through 4 Down Down Down , risk factors or risk markers for a first stroke were
classified according to potential for modification (nonmodifiable, modifiable, or potentially
modifiable) and strength of ... Cited by 768 - Related articles - BL Direct - All 13 versions
J Ansell, J Hirsh, J Dalen, H Bussey, D Anderson, L … - Chest, 2001 - chestjournal.chestpubs.org Several important developments in the last 2 decades have improved clinical outcomes with oral
anticoagulation therapy and have led to an appropriate increase in the use of this therapy by
improving its safety. These ... Cited by 468 - Related articles - BL Direct - All 7 versions
MA Crowther, JS Ginsberg, J Julian, J … - The New England …, 2003 - nejm.highwire.org Methods We performed a randomized, double-blind trial in which patients with antiphospholipid
antibodies and previous thrombosis were assigned to receive enough warfarin to achieve an INR of 2.0
to 3.0 (moderate intensity) or 3.1 ... Cited by 353 - Related articles - BL Direct - All 6 versions
- ►bloodjournal.org M Galli, D Luciani, G Bertolini, T Barbui - Blood, 2003 - Am Soc Hematology Antiphospholipid antibodies are a heterogeneous family of immunoglobulins that includes, among
others, lupus anticoagulants and anticardiolipin antibodies. Lupus anticoagulants behave as acquired
inhibitors of coagulation, ... Cited by 345 - Related articles - BL Direct - All 7 versions
G Finazzi, V Brancaccio, M Moia, N Ciavarella, MG … - The American journal of …, 1996 - Elsevier Thirty-four patients developed a thrombotic complication, with a total incidence of 2.5%
patient-years. Multivariate logistic regression analysis identified two independent risk factors for
thrombotic events: a previous ... Cited by 301 - Related articles - BL Direct - All 7 versions
MD Schulman… - The American journal of medicine, 1998 - Elsevier Results: Among the 412 patients with a first episode of venous thromboembolism the risk of
recurrence was 29% in patients with anticardiolipin antibodies and 14% in those without antibodies
(P = 0.0013). In those with ... Cited by 232 - Related articles - BL Direct - All 3 versions
- ►hem-aids.ru [PDF] RL Bick - Hematology/oncology clinics of North America, 2003 - Elsevier Antiphospholipid thrombosis syndromes, which include not only the lupus anticoagulant (LA) and
anticardiolipin antibodies (ACLAs) but also more recently recognized “subgroups” of
antiphospholipid antibodies ... Cited by 228 - Related articles - BL Direct - All 14 versions
